Abstract 5557: EnanDIM, a family of potent enantiomeric TLR9 agonists, modulate the tumor microenvironment and show single-agent antitumor effects in various syngeneic murine models
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-5557
Abstract: Introduction: TLR9 agonists, being recognized via non-methylated CG-motifs, target the Toll-like receptor 9 (TLR9). This way, they activate the innate and the adaptive immune system. Two different families of TLR9 agonists are currently used in… read more here.
Keywords: tlr9 agonists; various syngeneic; modulate tumor; syngeneic murine ... See more keywords
Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.13849
Abstract: Rhabdomyosarcoma (RMS), a neoplasm characterized by undifferentiated myoblasts, is the most common soft tissue tumour in children. Therapeutic resistance is common in RMS and is often caused by acquired defects in the cellular apoptotic program.… read more here.
Keywords: smac mimetic; murine; oncolytic virus; mimetic compounds ... See more keywords
Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes.
Sign Up to like & getrecommendations! Published in 2022 at "Neurosurgical focus"
DOI: 10.3171/2021.11.focus21556
Abstract: Glioblastoma is the most common primary malignant brain neoplasm with dismal 10-year survival rates of < 1%. Despite promising preliminary results from several novel therapeutic agents, clinical responses have been modest due to several factors,… read more here.
Keywords: glioblastoma models; syngeneic murine; models reactionary; murine glioblastoma ... See more keywords